upadacitinib
abbvie
[' upa ', 'crohn', 'ibd']
prof feagan - again v. impressive endoscopic outcomes w upa for #crohns in phase-3 rct; nnt = 3 is unprecedented in either bio-naive or bio-ir pts. dose-response (30 vs. 15 mg) seen at the end of 52 weeks suggesting that bio-ir pts will likely need 30 mg #ddw2023 #ibd
Swedish physician specializing in the treatment of Crohn's disease and Ulcerative Colitis. Views - my own.